Gynecologic Cancer Intergroup (GCIG) consensus review for ovarian germ cell tumors

Jubilee Brown1, Michael Friedlander, Floor J Backes

  • 1*University of Texas MD Anderson Cancer Center, Houston, TX (Gynecologic Oncology Group [GOG]); †Prince of Wales Hospital, Sydney, Australia (Australia and New Zealand Gynecological Oncology Group [ANZGOG]); ‡The Ohio State University, Columbus, OH (GOG); §Kliniken Essen-Mitte, Essen, Germany (AGO); ∥University of Louisville, Louisville, KY (GOG); ¶Institut Curie, Hôpital Rene Huguenin, Saint Cloud, France (Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens [GINECO]); #Fondazione IRCCS National Cancer Institute of Milan, Italy (Multicentre Italian Trials in Ovarian Cancer); **Tampere University Hospital, Tampere, Finland (Nordic Society of Gynaecological Oncology); ††Seoul National University College of Medicine, Seoul, Korea (Korean Gynecologic Oncology Group); ‡‡The University of Chicago, Chicago, IL (GOG); and §§Charing Cross Hospital, London, UK (Medical Research Council/National Cancer Research Institute [MRC NCRI]).

Summary

Malignant ovarian germ cell tumors are highly curable in most women, with fertility-sparing options available. Global consensus guidelines now standardize diagnosis and management for improved patient outcomes.